				Supplementary Table II. Baseline patient characteristics in the included studies			
Study	Group	Age (yr)	BMI (kg/m²)	FBG (mmol/L)	HOMA-IR	TT (nmol/L)	FAI
Javed et al[9]	EMPA (n=19)	26±8	37.1±6.2	4.5 (0.6)	2.6 (2.1)	1.6±0.4	10.3±3
	MET (n=20)	31.5±20	38.7±7.8	4.7 (0.5)	3.7 (2.4)	1.7 (1.2)	7.5 (6.4)
Tan et al[10]	LICO (n=15)	26·1±4·76	36·8±4·39	4·57±0·62	7·54±4·61	1·98±0·84	12·4±6·65
	Placebo (n=14)	29·1±5·66	39·5±7·74	4·29±0·47	6·22±3·28	2·07±0·61	9·0±2·77
Cai et al[11]	CANA (n=33)	28.58 (26.72-30.43)	27.26 (25.55-28.99)	5.18 (4.99 -5.38)	5.33 (3.92-6.73)	6.17 (5.27-7.1)	NA
	MET (n=35)	27.83 (25.97-29.68)	27.95 (26.22-29.69)	5.17 (5.0-5.34)	4.61 (3.42-5.80)	5.89 (4.96-6.8)	NA
Elkind-Hirsch et al[12]	DAPA (n=17)	28±1.5	38±1.1	5.44±0.13	4.1±0.7	1.59±0.17	6.7±1.0
	EQW (n=20)	30±1.1	38.6±1.1	5.23±0.09	3.9±0.7	1.63±0.15	6.8±0.94
Zhang et al[13]	CANA/MET (n=21)	26.38±5.89	31.11±3.02	5.7 (5.27-6.02)	5.70 (3.38-6.08)	3.29 (2.7-3.74)	28.62±16.4
	MET (n=20)	25.55±4.36	29.33±3.19	5.30 (5.16-5.80)	4.25 (3.26-6.44)	3.09 (2.57-3.78)	19.26±9.46

n=no. of participants. BMI, body mass index; CANA, canagliflozin; DAPA, dapagliflozin; EMPA, empagliflozin; EQW, exenatide; FBG, fasting blood glucose; FAI, free androgen index; HOMA-IR, homeostasis model assessment-estimated insulin resistance; LICO, licogliflozin; MET, metformin; TT, total testosterone